enzomenib + venetoclax + azacitidine

A novel oral pharmaceutical combination comprising enzomenib, a menin-MLL (KMT2A) interaction inhibitor, venetoclax, a BCL-2 inhibitor, and azacitidine, a hypomethylating agent. - **Enzomenib** is an investigational small molecule targeting the menin and mixed-lineage leukemia (MLL; KMT2A) protein interaction, thereby disrupting oncogenic gene expression programs driven by KMT2A rearrangements or NPM1 mutations, and is in clinical development for acute myeloid leukemia (AML), particularly relapsed/refractory disease. - **Venetoclax** is a selective inhibitor of the anti-apoptotic protein BCL-2, frequently used in combination regimens for AML and other hematologic malignancies to induce apoptosis in malignant cells. - **Azacitidine** is a nucleoside metabolic inhibitor/hypomethylating agent approved for treatment of myelodysplastic syndromes (MDS) and AML, working mainly by inhibiting DNA methylation and promoting re-expression of silenced genes involved in differentiation and apoptosis. - The combination is deployed for the treatment of acute leukemia, especially for patients with KMT2A rearrangements or NPM1 mutations, aiming to combine epigenetic reprogramming, apoptosis induction, and targeted gene regulation disruption for synergistic anti-leukemia effects[1][3][5]. - This combination is under investigation as a multi-agent protocol in clinical trials for relapsed/refractory AML.